Condition: Drug-resistant Tuberculosis · HIV Coinfection · Cost-Benefit Analysis · Sponsor: University of California, San Francisco
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.
This description comes directly from the study's public registry record.
John Z Metcalfe, MD, PhD · +14152068314 · john.metcalfe@ucsf.edu
Rob Warren, PhD
Always discuss trial participation with your own doctor first.
| South African National Health Laboratory Service | Cape Town, South Africa | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05553236